Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics (NQ: HZNP )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Horizon Therapeutics

< Previous 1 2 3 4 5 6 7 8 9 Next >
Rule 17(e) Announcement - Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics PLC (NASDAQ: HZNP) Climbs to New 52-Week High
Via Investor Brand Network
Rule 17(d) Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics PLC (NASDAQ: HZNP) Climbs to New 52-Week High
Via Investor Brand Network
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023
From Horizon Therapeutics plc
Via Business Wire
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes
From Horizon Therapeutics plc
Via Business Wire
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics PLC (NASDAQ: HZNP) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry
From Horizon Therapeutics plc
Via Business Wire
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List
From Horizon Therapeutics plc
Via Business Wire
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement
From Horizon Therapeutics plc
Via Business Wire
3 Growth Stocks to Buy in September
As the calendar turns to September, optimistic investors will look for value in quality companies with a history of generating strong revenue and earnings 
Via MarketBeat
Topics Economy
Exposures Economy
Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
From Horizon Therapeutics plc
Via Business Wire
Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition
From Horizon Therapeutics plc and Amgen
Via Business Wire
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups
From Horizon Therapeutics plc
Via Business Wire
Drinks, Chips & Drugs: A Surprising List of 10-Year Stock Winners
A handful of large caps have taken things to another level. These three stocks have blown past the herd — and may be market leaders for years to come. 
Via MarketBeat
Topics Bankruptcy Economy
Exposures Economy Financial Legal
Horizon Therapeutics plc - Rule 2.12 Announcement
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results
From Horizon Therapeutics plc
Via Business Wire
Is Growth Priced into Amgen Stock after Earnings Beat?
Amgen earnings delivered a solid earnings report after the market closed but analyst sentiment suggests that growth may already be priced into AMGN stock. 
Via MarketBeat
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Daxdilimab for the Treatment of Systemic Lupus Erythematosus (SLE) Did Not Meet Primary Endpoint
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Release Second-Quarter 2023 Financial Results on Aug. 8, 2023
From Horizon Therapeutics plc
Via Business Wire
Activision Surges 10% As Judge OK's Microsoft Acquisition Deal
Following a federal judge's OK of Microsoft's acquisition, Activision shares soared 10%, marking their strongest performance in over a year. The FTC can appeal. 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.